In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial.

Panelists discuss how the pooled 3-year data for delandistrogene moxeparvovec show sustained motor function stabilization and less deterioration compared with natural history, providing confidence in ...

Researchers at the USF Health Morsani College of Medicine have identified a potential pathway that could protect cardiac ...

New market intelligence highlights therapeutic innovation, expanding treatment access and strategic investment as key drivers of global growth. Duchenne Muscular Dystrophy Treatment Market Duchenne ...

Panelists discuss how data from MDA 2025 demonstrate that delandistrogene moxeparvovec (gene therapy for DMD) shows statistically significant improvements in motor function outcomes including North ...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...

Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...

The U.S. Food and Drug Administration will hold an advisory committee meeting to review the biologics license application for Capricor’s DMD therapy on July 29 ...

Duchenne muscular dystrophy (DMD) is a genetic disorder that mainly affects boys. DMD is usually diagnosed in early childhood and tends to worsen over time. DMD happens when a change (mutation) in the ...

Capricor is working toward a potential FDA decision by Aug. 22, making the next two months a key regulatory stretch for CAPR investors.

Sarepta Therapeutics said it has temporarily suspended shipments of Elevidys ® (delandistrogene moxeparvovec-rokl) for infusion in non-ambulatory patients following the second death in three months of ...